Lynparza leads the way with third approved indication in Europe

18 June 2019

UK-based drugmaker AstraZeneca (LSE: AZN) has announced European approval for Lynparza (olaparib), as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.

Together with US-based development partner Merck & Co (NYSE: MRK), the firm won US approval for the label expansion in December 2018.

The decision marks the third indication, and the second type of cancer approved for the PARP blocker, after breast cancer. Shares in the AstraZeneca were up over 1% in early trading on Tuesday morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK